文献速递放疗物理与技术

基于电子射野影像装置进行IMRT和VMAT在体治疗验证的方法

A method for in vivo treatment verification of IMRT and VMAT based on electronic portal imaging device.
PubMed 文献 · Radiat Oncol · 2021-12-04

本研究开发了一种基于电子射野影像装置的在体治疗验证模型,利用放疗计划中的注量图预测EPID透射图像并与实测图像比较。采用CIRS胸部模体和20例临床计划(10例IMRT和10例VMAT)评估,3%/2 mm全局伽马分析通过率IMRT大于97.2%、VMAT大于94.5%。

要点

  • 基于计划注量图预测EPID透射图像,用于IMRT和VMAT在体治疗验证。
  • 3%/2 mm全局伽马分析通过率IMRT大于97.2%、VMAT大于94.5%。
  • 模型经CIRS胸部模体和20例头颈、乳腺、直肠临床计划评估。

核心结论

  • 作者开发了一种准确且直接的基于EPID的质量保证模型,有可能用于IMRT和VMAT照射的在体治疗验证。

研究设计与样本

  • 研究从放疗计划中提取注量图,经半影、响应、整体野输出、衰减和散射校正后计算透射图像。
  • 模型参数利用一系列EPID测量数据分别针对中心轴和离轴点计算。
  • 采用CIRS胸部模体和20例临床计划(10例IMRT和10例VMAT)评估模型,计划针对头颈、乳腺和直肠治疗优化。

主要发现

  • 采用3%/2 mm(10%阈值)全局伽马分析比较预测与实测图像,IMRT和VMAT的伽马通过率分别大于97.2%和大于94.5%。

关键数值与推荐

  • 伽马分析条件为3%/2 mm、10%阈值。
  • IMRT伽马通过率大于97.2%,VMAT伽马通过率大于94.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intensity-modulated radiation therapy (IMRT) and volume-modulated arc therapy (VMAT) are rather complex treatment techniques and require patient-specific quality assurance procedures. Electronic portal imaging devices (EPID) are increasingly used in the verification of radiation therapy (RT). This work aims to develop a novel model to predict the EPID transmission image (TI) with fluence maps from the RT plan. The predicted TI is compared with the measured TI for in vivo treatment verification. METHODS: The fluence map was extracted from the RT plan and corrections of penumbra, response, global field output, attenuation, and scatter were applied before the TI was calculated. The parameters used in the model were calculated separately for central axis and off-axis points using a series of EPID measurement data. Our model was evaluated using a CIRS thorax phantom and 20 clinical plans (10 IMRT and 10 VMAT) optimized for head and neck, breast, and rectum treatments. RESULTS: Comparisons of the predicted and measured images were carried out using a global gamma analysis of 3%/2 mm (10% threshold) to validate the accuracy of the model. The gamma pass rates for IMRT and VMAT were greater than 97.2% and 94.5% at 3%/2 mm, respectively. CONCLUSION: We have developed an accurate and straightforward EPID-based quality assurance model that can potentially be used for in vivo treatment verification of the IMRT and VMAT delivery.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Li X, Lu M, et al. A method for in vivo treatment verification of IMRT and VMAT based on electronic portal imaging device. Radiat Oncol. 2021. PMID: 34863229. doi:10.1186/s13014-021-01953-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。